Shares of New York-based Omrix Biopharmaceuticals shot up on a report in the Israeli-based Globes that a New York hedge fund had offered to acquire the biotech company for $25 a share--a 13 percent premium on its Friday close. Citing unnamed sources, the Globes report also said that Omrix had rejected a buyout bid by Johnson & Johnson. Omrix does R&D work in Israel. Omrix makes products that control bleeding.
--read the AP report [1]
Related Articles:
OMRIX Biopharmaceuticals Receives FDA Approval for Thrombin [2]
Omrix outlines plan for $55M offering [3]
Links:
[1] http://www.forbes.com/feeds/ap/2008/08/18/ap5335204.html
[2] http://www.fiercebiotech.com/press-releases/press-release-omrix-biopharmaceuticals-receives-fda-approval-thrombin
[3] http://www.fiercebiotech.com/story/omrix-outlines-plan-for-55m-offering/2006-03-27